Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

INTRODUCTION: The first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Soria, Anna, Calvo, Mariona, Casas, Meritxell, Vidales, Zara, Muñoz-Martínez, Sergio, Sapena, Victor, Puigvehi, Marc, Canillas, Lidia, Guardeño, Raquel, Gallego, Adolfo, Mínguez, Beatriz, Horta, Diana, Clos, Ariadna, Montoliu, Silvia, Roget, Mercè, Reig, Maria, Vergara, Mercedes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380437/
https://www.ncbi.nlm.nih.gov/pubmed/35982971
http://dx.doi.org/10.3389/fonc.2022.829483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380437/
https://www.ncbi.nlm.nih.gov/pubmed/35982971
http://dx.doi.org/10.3389/fonc.2022.829483

Ejemplares similares